CIK 0001782223 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831160910
- Phone
- (617) 221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- Open-market buys, last 90 days
- $0
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 4 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-13 | Bayer World Investments B.V. Former 10% Owner | Conversion | +2,742,338 | 2,742,338 | ||
| 2021-10-13 | Bayer World Investments B.V. Former 10% Owner | Conversion · Series A Convertible Preferred Stock | −11,362,462 | 0 | ||
| 2021-10-13 | Bayer World Investments B.V. Former 10% Owner | Conversion · Series B Convertible Preferred Stock | −6,076,072 | 0 | ||
| 2021-10-13 | Cormorant Asset Management, LP Former 10% Owner | Conversion | +668,854 | 668,854 | ||
| 2021-10-13 | Cormorant Asset Management, LP Former 10% Owner | Purchase | +450,000 | $16.00 | $7.2M | 1,118,854 |
| 2021-10-13 | Cormorant Asset Management, LP Former 10% Owner | Conversion · Series B Convertible Preferred Stock | −668,854 | 0 | ||
| 2021-10-13 | Chin Mark Director | Conversion | +1,433,261 | 1,433,261 | ||
| 2021-10-13 | Chin Mark Director | Purchase | +312,500 | $16.00 | $5.0M | 1,745,761 |
| 2021-10-13 | Chin Mark Director | Conversion · Series B Convertible Preferred Stock | −9,114,109 | 0 | ||
| 2021-10-13 | FLAVIN JOHN L Director | Conversion | +2,388 | 171,610 | ||
| 2021-10-13 | FLAVIN JOHN L Director | Conversion · Series B Convertible Preferred Stock | −15,190 | 0 | ||
| 2021-10-07 | Civik Thomas Director | Grant or award · Stock Option (Right to buy) | +42,191 | 42,191 | ||
| 2021-10-07 | FLAVIN JOHN L Director | Grant or award · Stock Option (Right to buy) | +42,191 | 42,191 | ||
| 2021-10-07 | Cline Darren S Director | Grant or award · Stock Option (Right to buy) | +42,191 | 42,191 | ||
| 2021-10-07 | Feingold Jay Chief Medical Officer | Grant or award | +43,750 | 43,750 | ||
| 2021-10-07 | Feingold Jay Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +436,929 | 436,929 | ||
| 2021-10-07 | Chin Mark Director | Grant or award · Stock Option (Right to buy) | +42,191 | 42,191 |
Page 7 of 7 · 137 trades